Yung Zip Chemical Ind. Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2018
November 11, 2018 at 01:40 pm EST
Share
Yung Zip Chemical Ind. Co., Ltd. announced earnings results for the third quarter ended September 30, 2018. For the third quarter, the company announced sales was TWD 92.847 million compared to TWD 80.373 million a year ago. Operating loss was TWD 6.210 million compared to TWD 2.852 million a year ago. Net loss was TWD 3.746 million compared to TWD 2.998 million a year ago. Basic loss per share was TWD 0.09 compared to TWD 0.07 a year ago.
For the nine months, sales was TWD 242.239 million compared to TWD 232.711 million a year ago. Operating loss was TWD 21.259 million compared to TWD 24.956 million a year ago. Net loss was TWD 15.806 million compared to TWD 28.593 million a year ago. Basic loss per share was TWD 0.37 compared to TWD 0.67 a year ago.
YUNG ZIP CHEMICAL IND. CO., LTD. is a Taiwan-based company principally engaged in the manufacturing and trading of pharmaceutical ingredient products. Its diclofenac sodium (DCS) is used for the treatment of rheumatoid arthritis, bursitis and inflammation. The acyclovir (ACV) is used for the treatment of herpes virus infections. The miconazole nitrate (MCN) is used for the treatment of yeast infection. The sodium starch glycolate (SSG) is used as disintegrant in pharmaceutical preparation. The Clonidine hydrochloride (CLD) is used for the treatment of hypertension. The Company mainly distributes its products in domestic market and overseas markets, including the United States of America (the USA), Thailand, Indonesia and the Philippines.
YUNG ZIP CHEMICAL IND. CO., LTD. 
